An analysis of the Cancer Genome Atlas (TCGA) RNA-sequencing data from non-hematopoietic cancer types disclosed that elevated FCRL6 expression in the tumor microenvironment correlates with improved overall survival and progression-free survival in melanoma, breast cancer and non-small cell lung cancer [12]. Here, FCRL6 is linked to non-small cell lung carcinoma.